Pain and Catastrophizing in Patients With Rheumatoid Arthritis: An Observational Cohort Study

Ezra M. Cohen, Robert R. Edwards, Clifton Bingham, Kristine Phillips, Marcy B. Bolster, Larry W. Moreland, Tuhina Neogi, Wendy Marder, Alyssa Wohlfahrt, Daniel Clauw, Yvonne C. Lee

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The aims of this study were to define changes in catastrophizing that occur with initiation of a new disease-modifying antirheumatic drug (DMARD) and to examine the relationship between changes in Clinical Disease Activity Index (CDAI) and changes in catastrophizing. METHODS: Participants in an ongoing multisite, observational study completed the Pain Catastrophizing Scale (PCS) before and 12 weeks after DMARD initiation. We used multivariable linear regression models to examine the association between changes in CDAI as the exposure and change in pain catastrophizing as the outcome. We also assessed the relationship between changes in each component of CDAI and change in PCS, using multivariable linear regression models. RESULTS: Among the 165 rheumatoid arthritis patients with data on CDAI at both time points, CDAI decreased from 22 to 11.5 on a 76-point scale (p < 0.0001) after 12 weeks. Pain intensity decreased from a median of 5 to 3 on a 10-point numeric rating scale (p < 0.0001), and catastrophizing decreased, from 16.0 to 12.0 on the 52-point PCS (p = 0.0005). Among the 163 with complete data for the regression analysis, changes in CDAI were positively correlated with changes in catastrophizing (standardized β = 0.19, p = 0.01). Of the components of the CDAI, change in assessor global score was most strongly associated with changes in catastrophizing (standardized β = 0.24, p = 0.003). CONCLUSIONS: Pain catastrophizing decreases, in conjunction with disease activity, after initiation of a new DMARD. These findings provide support for catastrophizing as a dynamic construct that can be altered with treatment directed at decreasing inflammatory disease activity and pain.

Original languageEnglish (US)
Pages (from-to)232-236
Number of pages5
JournalJournal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Volume25
Issue number5
DOIs
StatePublished - Aug 1 2019

Fingerprint

Catastrophization
Observational Studies
Rheumatoid Arthritis
Cohort Studies
Antirheumatic Agents
Linear Models
Pain

ASJC Scopus subject areas

  • Rheumatology

Cite this

Pain and Catastrophizing in Patients With Rheumatoid Arthritis : An Observational Cohort Study. / Cohen, Ezra M.; Edwards, Robert R.; Bingham, Clifton; Phillips, Kristine; Bolster, Marcy B.; Moreland, Larry W.; Neogi, Tuhina; Marder, Wendy; Wohlfahrt, Alyssa; Clauw, Daniel; Lee, Yvonne C.

In: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, Vol. 25, No. 5, 01.08.2019, p. 232-236.

Research output: Contribution to journalArticle

Cohen, Ezra M. ; Edwards, Robert R. ; Bingham, Clifton ; Phillips, Kristine ; Bolster, Marcy B. ; Moreland, Larry W. ; Neogi, Tuhina ; Marder, Wendy ; Wohlfahrt, Alyssa ; Clauw, Daniel ; Lee, Yvonne C. / Pain and Catastrophizing in Patients With Rheumatoid Arthritis : An Observational Cohort Study. In: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2019 ; Vol. 25, No. 5. pp. 232-236.
@article{6c39af01f5e44cb382467b2f03ebf36f,
title = "Pain and Catastrophizing in Patients With Rheumatoid Arthritis: An Observational Cohort Study",
abstract = "BACKGROUND: The aims of this study were to define changes in catastrophizing that occur with initiation of a new disease-modifying antirheumatic drug (DMARD) and to examine the relationship between changes in Clinical Disease Activity Index (CDAI) and changes in catastrophizing. METHODS: Participants in an ongoing multisite, observational study completed the Pain Catastrophizing Scale (PCS) before and 12 weeks after DMARD initiation. We used multivariable linear regression models to examine the association between changes in CDAI as the exposure and change in pain catastrophizing as the outcome. We also assessed the relationship between changes in each component of CDAI and change in PCS, using multivariable linear regression models. RESULTS: Among the 165 rheumatoid arthritis patients with data on CDAI at both time points, CDAI decreased from 22 to 11.5 on a 76-point scale (p < 0.0001) after 12 weeks. Pain intensity decreased from a median of 5 to 3 on a 10-point numeric rating scale (p < 0.0001), and catastrophizing decreased, from 16.0 to 12.0 on the 52-point PCS (p = 0.0005). Among the 163 with complete data for the regression analysis, changes in CDAI were positively correlated with changes in catastrophizing (standardized β = 0.19, p = 0.01). Of the components of the CDAI, change in assessor global score was most strongly associated with changes in catastrophizing (standardized β = 0.24, p = 0.003). CONCLUSIONS: Pain catastrophizing decreases, in conjunction with disease activity, after initiation of a new DMARD. These findings provide support for catastrophizing as a dynamic construct that can be altered with treatment directed at decreasing inflammatory disease activity and pain.",
author = "Cohen, {Ezra M.} and Edwards, {Robert R.} and Clifton Bingham and Kristine Phillips and Bolster, {Marcy B.} and Moreland, {Larry W.} and Tuhina Neogi and Wendy Marder and Alyssa Wohlfahrt and Daniel Clauw and Lee, {Yvonne C.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1097/RHU.0000000000000834",
language = "English (US)",
volume = "25",
pages = "232--236",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Pain and Catastrophizing in Patients With Rheumatoid Arthritis

T2 - An Observational Cohort Study

AU - Cohen, Ezra M.

AU - Edwards, Robert R.

AU - Bingham, Clifton

AU - Phillips, Kristine

AU - Bolster, Marcy B.

AU - Moreland, Larry W.

AU - Neogi, Tuhina

AU - Marder, Wendy

AU - Wohlfahrt, Alyssa

AU - Clauw, Daniel

AU - Lee, Yvonne C.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - BACKGROUND: The aims of this study were to define changes in catastrophizing that occur with initiation of a new disease-modifying antirheumatic drug (DMARD) and to examine the relationship between changes in Clinical Disease Activity Index (CDAI) and changes in catastrophizing. METHODS: Participants in an ongoing multisite, observational study completed the Pain Catastrophizing Scale (PCS) before and 12 weeks after DMARD initiation. We used multivariable linear regression models to examine the association between changes in CDAI as the exposure and change in pain catastrophizing as the outcome. We also assessed the relationship between changes in each component of CDAI and change in PCS, using multivariable linear regression models. RESULTS: Among the 165 rheumatoid arthritis patients with data on CDAI at both time points, CDAI decreased from 22 to 11.5 on a 76-point scale (p < 0.0001) after 12 weeks. Pain intensity decreased from a median of 5 to 3 on a 10-point numeric rating scale (p < 0.0001), and catastrophizing decreased, from 16.0 to 12.0 on the 52-point PCS (p = 0.0005). Among the 163 with complete data for the regression analysis, changes in CDAI were positively correlated with changes in catastrophizing (standardized β = 0.19, p = 0.01). Of the components of the CDAI, change in assessor global score was most strongly associated with changes in catastrophizing (standardized β = 0.24, p = 0.003). CONCLUSIONS: Pain catastrophizing decreases, in conjunction with disease activity, after initiation of a new DMARD. These findings provide support for catastrophizing as a dynamic construct that can be altered with treatment directed at decreasing inflammatory disease activity and pain.

AB - BACKGROUND: The aims of this study were to define changes in catastrophizing that occur with initiation of a new disease-modifying antirheumatic drug (DMARD) and to examine the relationship between changes in Clinical Disease Activity Index (CDAI) and changes in catastrophizing. METHODS: Participants in an ongoing multisite, observational study completed the Pain Catastrophizing Scale (PCS) before and 12 weeks after DMARD initiation. We used multivariable linear regression models to examine the association between changes in CDAI as the exposure and change in pain catastrophizing as the outcome. We also assessed the relationship between changes in each component of CDAI and change in PCS, using multivariable linear regression models. RESULTS: Among the 165 rheumatoid arthritis patients with data on CDAI at both time points, CDAI decreased from 22 to 11.5 on a 76-point scale (p < 0.0001) after 12 weeks. Pain intensity decreased from a median of 5 to 3 on a 10-point numeric rating scale (p < 0.0001), and catastrophizing decreased, from 16.0 to 12.0 on the 52-point PCS (p = 0.0005). Among the 163 with complete data for the regression analysis, changes in CDAI were positively correlated with changes in catastrophizing (standardized β = 0.19, p = 0.01). Of the components of the CDAI, change in assessor global score was most strongly associated with changes in catastrophizing (standardized β = 0.24, p = 0.003). CONCLUSIONS: Pain catastrophizing decreases, in conjunction with disease activity, after initiation of a new DMARD. These findings provide support for catastrophizing as a dynamic construct that can be altered with treatment directed at decreasing inflammatory disease activity and pain.

UR - http://www.scopus.com/inward/record.url?scp=85070527814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070527814&partnerID=8YFLogxK

U2 - 10.1097/RHU.0000000000000834

DO - 10.1097/RHU.0000000000000834

M3 - Article

C2 - 30035754

AN - SCOPUS:85070527814

VL - 25

SP - 232

EP - 236

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 5

ER -